Dimensional Fund Advisors LP Has $3.24 Million Stock Holdings in OptimizeRx Co. (NASDAQ:OPRX)

Dimensional Fund Advisors LP raised its stake in OptimizeRx Co. (NASDAQ:OPRX) by 12.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 324,130 shares of the company’s stock after buying an additional 35,957 shares during the period. Dimensional Fund Advisors LP’s holdings in OptimizeRx were worth $3,241,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. G2 Investment Partners Management LLC boosted its holdings in shares of OptimizeRx by 26.0% during the 4th quarter. G2 Investment Partners Management LLC now owns 468,120 shares of the company’s stock valued at $6,699,000 after acquiring an additional 96,646 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of OptimizeRx during the first quarter valued at about $1,053,000. Vanguard Group Inc. grew its holdings in shares of OptimizeRx by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after purchasing an additional 6,291 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in shares of OptimizeRx by 23.5% in the second quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock valued at $4,961,000 after buying an additional 94,253 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in OptimizeRx by 9.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock valued at $1,117,000 after buying an additional 10,041 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OPRX. B. Riley assumed coverage on shares of OptimizeRx in a report on Thursday, July 25th. They set a “buy” rating and a $18.50 target price on the stock. Barclays reduced their price objective on shares of OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Monday, August 12th. JMP Securities reaffirmed a “market outperform” rating and set a $16.00 target price on shares of OptimizeRx in a research report on Friday, June 21st. Finally, Royal Bank of Canada reduced their price target on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

OptimizeRx Trading Up 2.8 %

NASDAQ:OPRX opened at $6.57 on Friday. OptimizeRx Co. has a 52 week low of $6.30 and a 52 week high of $16.65. The firm’s fifty day moving average is $7.95 and its 200-day moving average is $9.87. The firm has a market cap of $120.03 million, a P/E ratio of -6.44 and a beta of 1.27. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. OptimizeRx had a negative net margin of 21.53% and a negative return on equity of 5.97%. The business had revenue of $18.81 million for the quarter, compared to analysts’ expectations of $20.47 million. Equities analysts expect that OptimizeRx Co. will post -0.33 earnings per share for the current year.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.